



NOVAGALI PHARMA STRENGTHENS SENIOR MANAGEMENT TEAM

08 SEPTEMBER 2004 16:36

Jérôme Martinez is new company chairman and Dr Alain Munoz becomes president of the supervisory board

Novagali Pharma, a drug delivery specialist using cationic emulsions to address ophthalmic and other applications including oncology, announces today two senior appointments that add strength and experience to the company's management team. Jérôme Martinez, previously vice president business development becomes chairman of the company and Dr Alain Munoz takes up the position of president of the supervisory board.

In his new position, Jérôme Martinez will be responsible for developing Novagali as a business in France and internationally, and ensuring it remains on a sound financial footing. Martinez enjoys a scientific and sales background with 13 years' experience in drug delivery.

"Novagali Pharma is in a phase of rapid growth with several products in clinical trials," said Martinez. "The quality of our technology and products gives me great confidence in implementing a strategy that will ensure that growth continues."

As president of the supervisory board, Alain Munoz will be the main interface between the shareholders and the operational management of the company. Among his duties will be to maintain the balance between the objectives set by the supervisory board and the operational strategy within the company in close conjunction with Martinez.

"Novagali's technology has widespread therapeutic implications, especially in ophthalmology, and I have no doubt as to its future success," said Munoz. "I am delighted to be joining the company and working on this project."

Jérôme Martinez, 44, doctor of pharmacy (1983 – University of Paris XI), diploma in health law (1984 – University of Paris XI) MBA (1991 – HEC Jouy-en-Josas). Martinez worked as a pharmacist from 1983 to 1986, subsequently becoming deputy director of Alliance Santé, a pharmaceutical distributor. In 1991, he joined Roussel Uclaf in Tokyo where he was in charge of a pharmacoeconomics project, and in the same year Laboratoires Lavipharm in Paris as director of international marketing before being transferred to Princeton NJ, where he was vp marketing and business development of Lavipharm Inc. In 2001 he joined Ethypharm Corp. as senior vp business development and R&D for the USA and Canada. Returning to France, he took up a senior position at Laboratoires Ethypharm before joining Novagali Pharma in January 2004.

Alain Munoz, 55, MD (1976 – University of Paris VI) specialized on cardiology and anesthesiology. Trained to a high level in management and finance (CRC Jouy en Josas, IMD Lausanne). In 1976 he was a hospital intern at the Montpellier university hospital and then clinical director for cardiology. In 1983 he joined Sanofi's research division as director of the cardiovascular department, becoming project head for Sanofi's cardiovascular – antithrombotic range of products before taking the position of vp in charge of international development. He moved to the Fournier group in 1990 as vp R&D and in 1993 he added the licensing activities of the pharmaceutical division to his responsibilities. In 1997, he was appointed senior vp of the pharmaceutical division. Since 2000, he developed a number of independent activities related to biopharmaceutical investment, including the creation of Science and Business Development, a consultancy dedicated to project management in the healthcare sector.